Gliadin p31-43
Modify Date: 2025-08-25 18:23:03
Gliadin p31-43 structure
|
Common Name | Gliadin p31-43 | ||
|---|---|---|---|---|
| CAS Number | 176326-01-5 | Molecular Weight | 1527.68 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C71H102N18O20 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Gliadin p31-43Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research[1][2]. |
| Name | Gliadin p31-43 |
|---|
| Description | Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Gliadin p31-43 (100 μg/mL; 30 minutes-6 hours) treatment induces the MyD88/TLR7 complexes, and activates downstream signalling by activating MAPKs, ERK, JNK and p38). Gliadin p31-43 increases the levels of the phosphorylated forms of pY-ERK, JNK (pY-JNK) and p38 (pY-p38)[1]. Gliadin p31-43 treatment increases NF-κB phosphorylation in CaCo-2 cells from 0.45 in control cells to 0.86. Gliadin p31-43 treatment induces a significant increase in levels of the MxA protein. The levels of the IFN-α 7 and 17 mRNAs are also analysed after Gliadin p31-43 treatment[1]. In CaCo-2 cells, Gliadin p31-43 localizes to the early endosomes and delays vesicular trafficking. Gliadin p31-43 interferes with the correct localization of the growth factor regulated tyrosine kinase substrate (HRS) to early endosomes, delaying the maturation of the endocytic vesicles[1]. Western Blot Analysis[1] Cell Line: CaCo-2 cells Concentration: 100 μg/mL Incubation Time: 30 minutes, 3 hours, 6 hours Result: Showed the increase in formation of the MyD88/TLR7 complex, and increased in the level of TLR7. |
| In Vivo | Gliadin p31-43 (10 μg; intraluminally injection) shows a sequence-specific spontaneous ability to form structured oligomers and aggregates in vitro and induced activation of the apoptosis-associated speck-like (ASC) complex[2]. The increment of IL-1β indicates the activation of the inflammasome caspase-1 pathway in the small intestine mucosa by oral administration of Gliadin p31-43 (20 μg) in wild type C57Bl/6 mice. Gliadin p31-43 has an intrinsic propensity to form oligomers which trigger the NLRP3 inflammasome[2]. |
| References |
| Molecular Formula | C71H102N18O20 |
|---|---|
| Molecular Weight | 1527.68 |